ESSA Pharma Inc. (EPIX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.71+0.26 (+10.61%)
At close: 4:00 PM EDT
People also watch:
EMISCNCTENZNARQLINSM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open2.44
Prev Close2.45
Bid2.70 x 100
Ask2.94 x 600
Day's Range2.44 - 2.71
52wk Range2.25 - 7.00
1y Target EstN/A
Market Cap78.85M
P/E Ratio (ttm)-8.97
BetaN/A
Volume14,485
Avg Vol (3m)3,760
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • CNW Group15 days ago

    ESSA Pharma to present at Rodman & Renshaw 18th Annual Global Investment Conference

    ESSA Pharma to present at Rodman & Renshaw 18th Annual Global Investment Conference

  • PR Newswire15 days ago

    ESSA Pharma to present at Rodman & Renshaw 18th Annual Global Investment Conference

    HOUSTON, TX and VANCOUVER, Canada, Sept. 12, 2016 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced David R. Parkinson, President and Chief Executive Officer will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference in New York City on Tuesday September 13th at 11:15 AM Eastern Time at the Lotte New York Palace Hotel. Dr. Parkinson will provide a corporate overview of the Company's business and will be available for one-on-one meetings from September 12 – 13, 2016.  ESSA's Chief Financial Officer, David S. Wood and ESSA's Chief Operating Officer, Peter Virsik, will be also in attendance.  A live audio webcast of the presentation may be accessed by visiting  http://wsw.com/webcast/rrshq26/epi and will be available at the Company's website(www.essapharma.com) after the conference.

  • PR Newswirelast month

    ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016

    HOUSTON, TX and VANCOUVER, Aug. 12, 2016 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the third quarter and three months ended June 30, 2016.  Amounts, unless specified otherwise, are expressed in United States dollars and in accordance with International Financial Reporting Standards ("IFRS"). ESSA recorded a net loss of $3.9 million ($0.13 per common share) for the three months ended June 30, 2016, compared to a net loss of $4.9 million ($0.29 per common share) for the three months ended June 30, 2015. Research and Development ("R&D") expenditures for the three month period were $3.4 million compared to $2.6 million for 2015.  R&D expenditures in the period are primarily related to manufacturing and clinical costs as the Company continues its work in the clinical development stage with respect to clinical candidate EPI-506.